Drug Trial Radar · NCT07340320
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
251
Actual
Start
Feb 6, 2026
Primary completion
Apr 8, 2027
Study completion Apr 15, 2027
Sponsor
- Lead sponsor
- Corxel PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jan 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug. After screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.
Conditions
- Type II Diabetes Mellitus
Interventions
CX11Drug
CX11 tablets administered orally once daily (QD)
PlaceboOther
Matching placebo tablets administered orally once daily (QD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Glycosylated hemoglobin, Type A1C (HbA1c) from baselineTime frame: At Week 24
Locations
44 sites in 2 countries. Site status is shown where the registry gives one.
Central Research Associates - Flourish - PPDS
Birmingham, Alabama
AES - DRS - Synexus Clinical Research US, Inc. - Birmingham
Birmingham, Alabama
AES - DRS - Optimal Research Alabama - Huntsville
Huntsville, Alabama
Core Healthcare Group
Cerritos, California
Ark Clinical Research - Long Beach
Long Beach, California
Flourish Research - Walnut Creek - PPDS
Walnut Creek, California
AES - DRS - Optimal Research Florida - Melbourne
Melbourne, Florida
Tampa General Hospital
Tampa, Florida
Conquest Research LLC - Winter Park
Winter Park, Florida
Privia Medical Group Georgia, LLC - Albany - Javara - PPDS
Albany, Georgia
Javara Inc. - Fayetteville
Fayetteville, Georgia
Privia Medical Group Georgia, LLC - Savannah - Javara - PPDS
Savannah, Georgia
AES - DRS - Synexus Clinical Research US, Inc. - Chicago
Chicago, Illinois
AES - DRS - Synexus Clinical Research US, Inc. - Evansville
Evansville, Indiana
Privia Medical Group, LLC - Kelly's Collaborative Care - Javara - PPDS
Silver Spring, Maryland
Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS
Pontiac, Michigan
AES - DRS - Synexus Clinical Research US, Inc. - Edina - Minneapolis
Edina, Minnesota
Mankato Clinic - East Main Street - Javara - PPDS
Mankato, Minnesota
Sky Integrative Medical Center
Ridgeland, Mississippi
Hassman Research Institute - Berlin - CenExel - PPDS
Berlin, New Jersey
Albuquerque Clinical Trials Inc
Albuquerque, New Mexico
Brooklyn Clinical Research
Brooklyn, New York
M3 Wake Research, Inc - M3 WR
Raleigh, North Carolina
M3 Wake Research - Dallas
Dallas, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
SMS Clinical Research, LLC - 400 W. Kearney St
Mesquite, Texas
AES - DRS - Synexus Clinical Research US, Inc. - San Antonio
San Antonio, Texas
Flourish Research - San Antonio - PPDS
San Antonio, Texas
Privia Medical Group- North Texas - Stephenville - Javara - PPDS
Stephenville, Texas
Conquest Research - Arlington
Vienna, Virginia
AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Poznaniu
Poznan, Greater Poland Voivodeship, Poland
Centrum Medyczne Pratia Bydgoszcz - PPDS
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne
Krakow, Lesser Poland Voivodeship, Poland
FutureMeds - Krakow - PPDS
Krakow, Lesser Poland Voivodeship, Poland
METABOLICA Sp. z o.o
Tarnów, Lesser Poland Voivodeship, Poland
AES - DRS - Synexus Polska Sp. Z o.o. Oddzial w Lodzi
Lodz, Lódzkie, Poland
FutureMeds - Lodz - PPDS
Lodz, Lódzkie, Poland
AES - DRS - Synexus Polska Sp. z o.o. Oddzial we Wroclawiu
Wroclaw, Lower Silesian Voivodeship, Poland
FutureMeds - Warszawa Centrum - PPDS
Warsaw, Masovian Voivodeship, Poland
AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Warszawie
Warsaw, Masovian Voivodeship, Poland
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.